03:13 PM EDT, 06/21/2024 (MT Newswires) -- Bristol-Myers Squibb's ( BMY ) combination therapy of Krazati with cetuximab for colorectal cancer treatment in patients with a specific gene mutation has received approval from the US Food and Drug Administration, the FDA website showed on Friday.
Bristol-Myers Squibb ( BMY ) added Krazati to its drug portfolio following the acquisition of Mirati Therapeutics in January.
Price: 41.77, Change: +0.73, Percent Change: +1.77